These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 31923859)

  • 1. Proton pump inhibitors selectively suppress MLL rearranged leukemia cells via disrupting MLL1-WDR5 protein-protein interaction.
    Chen WL; Li DD; Chen X; Wang YZ; Xu JJ; Jiang ZY; You QD; Guo XK
    Eur J Med Chem; 2020 Feb; 188():112027. PubMed ID: 31923859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of
    Chen W; Chen X; Li D; Zhou J; Jiang Z; You Q; Guo X
    J Med Chem; 2021 Jun; 64(12):8221-8245. PubMed ID: 34105966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
    Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X
    Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-affinity small molecular blockers of mixed lineage leukemia 1 (MLL1)-WDR5 interaction inhibit MLL1 complex H3K4 methyltransferase activity.
    Li DD; Chen WL; Wang ZH; Xie YY; Xu XL; Jiang ZY; Zhang XJ; You QD; Guo XK
    Eur J Med Chem; 2016 Nov; 124():480-489. PubMed ID: 27598236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design of ester compounds to inhibit MLL complex catalytic activity by targeting mixed lineage leukemia 1 (MLL1)-WDR5 interaction.
    Li DD; Wang ZH; Chen WL; Xie YY; You QD; Guo XK
    Bioorg Med Chem; 2016 Nov; 24(22):6109-6118. PubMed ID: 27720555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Piribedil disrupts the MLL1-WDR5 interaction and sensitizes MLL-rearranged acute myeloid leukemia (AML) to doxorubicin-induced apoptosis.
    Zhang X; Zheng X; Yang H; Yan J; Fu X; Wei R; Xu X; Zhang Z; Yu A; Zhou K; Ding J; Geng M; Huang X
    Cancer Lett; 2018 Sep; 431():150-160. PubMed ID: 29857126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.
    Karatas H; Townsend EC; Cao F; Chen Y; Bernard D; Liu L; Lei M; Dou Y; Wang S
    J Am Chem Soc; 2013 Jan; 135(2):669-82. PubMed ID: 23210835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Disruption of the Interaction between WD-40 Repeat Protein 5 (WDR5) and Mixed Lineage Leukemia (MLL)/SET1 Family Proteins Specifically Inhibits MLL1 and SETd1A Methyltransferase Complexes.
    Alicea-Velázquez NL; Shinsky SA; Loh DM; Lee JH; Skalnik DG; Cosgrove MS
    J Biol Chem; 2016 Oct; 291(43):22357-22372. PubMed ID: 27563068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-Based Optimization of a Small Molecule Antagonist of the Interaction Between WD Repeat-Containing Protein 5 (WDR5) and Mixed-Lineage Leukemia 1 (MLL1).
    Getlik M; Smil D; Zepeda-Velázquez C; Bolshan Y; Poda G; Wu H; Dong A; Kuznetsova E; Marcellus R; Senisterra G; Dombrovski L; Hajian T; Kiyota T; Schapira M; Arrowsmith CH; Brown PJ; Vedadi M; Al-Awar R
    J Med Chem; 2016 Mar; 59(6):2478-96. PubMed ID: 26958703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Development of Inhibitors Targeting the Mixed Lineage Leukemia 1 (MLL1)-WD Repeat Domain 5 Protein (WDR5) Protein- Protein Interaction.
    Ye X; Chen G; Jin J; Zhang B; Wang Y; Cai Z; Ye F
    Curr Med Chem; 2020; 27(33):5530-5542. PubMed ID: 31132972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design and synthesis of small molecular inhibitors disturbing the interaction of MLL1-WDR5.
    Li DD; Chen WL; Xu XL; Jiang F; Wang L; Xie YY; Zhang XJ; Guo XK; You QD; Sun HP
    Eur J Med Chem; 2016 Aug; 118():1-8. PubMed ID: 27116709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting protein-protein interaction between MLL1 and reciprocal proteins for leukemia therapy.
    Wang ZH; Li DD; Chen WL; You QD; Guo XK
    Bioorg Med Chem; 2018 Jan; 26(2):356-365. PubMed ID: 29254892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.
    Karatas H; Li Y; Liu L; Ji J; Lee S; Chen Y; Yang J; Huang L; Bernard D; Xu J; Townsend EC; Cao F; Ran X; Li X; Wen B; Sun D; Stuckey JA; Lei M; Dou Y; Wang S
    J Med Chem; 2017 Jun; 60(12):4818-4839. PubMed ID: 28603984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The identification of novel small-molecule inhibitors targeting WDR5-MLL1 interaction through fluorescence polarization based high-throughput screening.
    Ye X; Zhang R; Lian F; Zhang W; Lu W; Han J; Zhang N; Jin J; Luo C; Chen K; Ye F; Ding H
    Bioorg Med Chem Lett; 2019 Feb; 29(4):638-645. PubMed ID: 30626558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the H3K4 methyltransferase MLL1/WDR5 complex attenuates renal senescence in ischemia reperfusion mice by reduction of p16
    Shimoda H; Doi S; Nakashima A; Sasaki K; Doi T; Masaki T
    Kidney Int; 2019 Nov; 96(5):1162-1175. PubMed ID: 31570196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis for WDR5 interaction (Win) motif recognition in human SET1 family histone methyltransferases.
    Dharmarajan V; Lee JH; Patel A; Skalnik DG; Cosgrove MS
    J Biol Chem; 2012 Aug; 287(33):27275-89. PubMed ID: 22665483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct pathways affected by menin versus MLL1/MLL2 in MLL-rearranged acute myeloid leukemia.
    Chen Y; Jones KL; Anastassiadis K; Kranz A; Stewart AF; Grembecka J; Meyerson M; Ernst P
    Exp Hematol; 2019 Jan; 69():37-42. PubMed ID: 30315824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.
    Grembecka J; He S; Shi A; Purohit T; Muntean AG; Sorenson RJ; Showalter HD; Murai MJ; Belcher AM; Hartley T; Hess JL; Cierpicki T
    Nat Chem Biol; 2012 Jan; 8(3):277-84. PubMed ID: 22286128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
    Grebien F; Vedadi M; Getlik M; Giambruno R; Grover A; Avellino R; Skucha A; Vittori S; Kuznetsova E; Smil D; Barsyte-Lovejoy D; Li F; Poda G; Schapira M; Wu H; Dong A; Senisterra G; Stukalov A; Huber KVM; Schönegger A; Marcellus R; Bilban M; Bock C; Brown PJ; Zuber J; Bennett KL; Al-Awar R; Delwel R; Nerlov C; Arrowsmith CH; Superti-Furga G
    Nat Chem Biol; 2015 Aug; 11(8):571-578. PubMed ID: 26167872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
    Cao F; Townsend EC; Karatas H; Xu J; Li L; Lee S; Liu L; Chen Y; Ouillette P; Zhu J; Hess JL; Atadja P; Lei M; Qin ZS; Malek S; Wang S; Dou Y
    Mol Cell; 2014 Jan; 53(2):247-61. PubMed ID: 24389101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.